Evidence map›Paper›PMID 42830357›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026

Genetic susceptibility, risk prediction, and druggable targets for oropharyngeal cancer: a UK Biobank study.

Junhong Li, Ke Qiu, Yufang Rao, Danni Cheng, Yao Song, Xiuli Shao, Chuanhuan Jiang, Tao Shu, Wei Xu, Yu Zhao and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Junhong LiDepartment of Otolaryngology-Head & Neck Surgery, and, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
Ke QiuDepartment of Otolaryngology-Head & Neck Surgery, and, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
Yufang RaoDepartment of Otolaryngology-Head & Neck Surgery, and, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
Danni ChengDepartment of Otolaryngology-Head & Neck Surgery, and, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
Yao SongDepartment of Otolaryngology-Head & Neck Surgery, and, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
Xiuli ShaoDepartment of Otolaryngology-Head & Neck Surgery, and, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
Chuanhuan JiangDepartment of Otolaryngology-Head & Neck Surgery, and, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
Tao ShuDepartment of Otolaryngology-Head & Neck Surgery, and, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
Wei XuDepartment of Biostatistics, Princess Margaret Cancer Centre and Dalla Lana School of Public Health, Toronto, ON, Canada. Wei.Xu@uhnresearch.ca.
Yu ZhaoDepartment of Otolaryngology-Head & Neck Surgery, and, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China. yuzhao@wchscu.edu.cn.
Jianjun RenDepartment of Otolaryngology-Head & Neck Surgery, and, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China. Jianjun.Ren@scu.edu.cn.ORCID http://orcid.org/0000-0002-5938-688X

Funding

1·3·5 project for disciplines of excellence-Clinical Research Fund, West China Hospital, Sichuan University 2025HXFH0101·3·5 project for disciplines of excellence, West China Hospital, Sichuan University 2025-522Chengdu Science and Technology Bureau 2024-YF05-00908-SNNational Natural Science Foundation of China 82272777National Natural Science Foundation of China 82403589National Natural Science Foundation of China 82471153Science and Technology Department of Sichuan Province 2025ZNSFSC1528Science and Technology Department of Sichuan Province 2025ZNSFSC1530
6 · The paper itself

Abstract

purposeThis study aimed to systematically identify and annotate oropharyngeal cancer (OPC) genetic risk, construct OPC risk prediction models, and identify candidate drug targets for OPC treatment.

methodsThe OPC genome-wide association study was conducted in the UK Biobank involving 208 OPC patients and 328,248 healthy individuals. Functional annotations were performed using the FUMA website and the Sclinker statistical framework. OPC risk prediction models were constructed using logistic regression. Mendelian randomization (MR) was employed to identify potential OPC-related drug target genes.

resultsWe identified 43 OPC risk genetic variants with p < 1E-06, which mapped to 7 independent loci. We also revealed significant tissue-level OPC single nucleotide polymorphism heritability enrichments in heart, kidney, and muscle, and cell-type specific enrichments in B cells, T cells, endothelial cells, epithelial cells, and fibroblasts. We further constructed four OPC risk prediction models, and the fully-adjusted model demonstrated moderate discriminative ability in internal validation. Additionally, MR analysis identified 160 nominate OPC-associated candidate druggable genes using expression/protein quantitative trait loci as instrumental variables. Drugs targeting these genes, such as Daunorubicin, Gefitinib, and Ibrutinib had been approved as anti-cancer agents.

conclusionThese results advanced our understanding of the genetic architecture of OPC and provided insights into its risk prediction and potential drug targets, contributing to future development of improved OPC prevention and treatment strategies.

Indexed as

Druggable geneGenome-wide association studyMulti-omics characterizationOropharyngeal cancerRisk prediction model

Identifiers

PMID42830357

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.